HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

Location:

Rochester, Minn.

Trial status:

Open for Enrollment

Why is this study being done?

Aim 1: The clinical and virological status of chronic Hepatitis B (HBV) infection is defined by distinct patterns of immune effector and regulatory responses: The investigators propose that one or more immune regulatory are induced during chronic hepatitis B that define the extent of immune tolerance vs. activation with associated disease activity and viremia. Towards this end, the immune effector and regulatory responses relative to serum HBV DNA, alanine aminotransferase (ALT), Hepatitis B e antigen (HBeAg), Hepatitis B surface antigen (HBsAg) and liver histology will be examined in a cross-sectional manner in patients with chronic HBV and control groups. Aim 2: Clinical hepatitis flares during chronic hepatitis B reflect altered balance between immune regulatory and effector responses.

Who is eligible to participate?

Inclusion Criteria: • Providing informed consent for this ancillary study. Exclusion Criteria: - Children under 18 years of age, participants with anemia - Hgb<10 or Hct<30, congestive heart failure or chronic lung disease requiring oxygen, active coronary artery disease with unstable angina, sepsis or renal failure, other significant medical conditions, autoimmune disease or immunosuppression.

Last updated:

6/10/2014

NCT ID:

NCT01298037